Graft-versus-host disease (GVHD), graft rejection, disease recurrence and long-term toxicity remain significant obstacles to successful allogeneic bone marrow transplantation (BMT) in children with genetic diseases. In an attempt to improve results, we used a preparative regimen consisting of three alkylating agents, busulfan (BU), thiotepa (TTP) and cyclophosphamide (CY), for T cell-depleted allogeneic bone marrow transplantation instead of the conventional BU-CY protocol. The effect of this intensified regimen was investigated in 26 consecutive children with genetic diseases who underwent T cell-depleted BMT from HLA-identical siblings. Sixteen patients were males and 10 females, of median age 5 (0.2-14) years. The diseases included ␤-thalassemia major, osteopetrosis, severe combined immunodeficiency, Wiskott-Aldrich syndrome, familial agranulocytosis, congenital idiopathic hemolytic anemia (CIHA), Gaucher's disease, Niemann-Pick disease, Hurler's syndrome, and adrenoleukodystrophy. The conditioning regimen consisted of BU 4 mg/kg ؋ 4 days (؊8 to ؊5), TTP 5 mg/kg ؋ 2 days (؊4 and ؊3), and CY 60 mg/kg ؋ 2 days (؊2 and ؊1). Engraftment was as expected, with WBC Ͼ1.0 ؋ 10 9 /l at day +19 (10-33), ANC Ͼ0.5 ؋ 10 9 /l at day +22 (10-56) and platelets Ͼ25 ؋ 10 9 /l at day +32 (18-131). Transplant-related mortality was 19%. Overall survival and disease-free survival (DFS) at 60 months follow-up were both 77%. Our results with the BU-TTP-CY regimen followed by T cell-depleted BMT in genetic diseases may provide a basis for prospective comparison with the standard conditioning regimen of BU-CY in the management of children suffering from these conditions.
as severe combined immunodeficiency (SCID), osteopetrosis, ␤-thalassemia major, familial agranulocytosis, storage diseases such as Hurler's syndrome, and metabolic and lysosomal disorders including adrenoleukodystrophy. [3] [4] [5] [6] [7] [8] [9] [10] [11] However, graft-versus-host disease (GVHD), graft rejection, recurrence of disease, transplant-related toxicity and mortality remain major obstacles in the post-allogeneic BMT course, and despite the relative merits of this procedure for genetic diseases, it remains debatable because of these hazards.
There are a number of approaches which could perhaps be investigated with a view to lowering the risks involved, one of them being the intensification of the pre-transplant conditioning in conjunction with T cell depletion, which has already been evaluated in patients with hematologic malignancies. [12] [13] [14] This is an attractive approach, especially for diseases in which the stem cells are relatively resistant, [15] [16] [17] the aim being to attempt to reduce post-BMT disease recurrence with no risk of GVHD, and to avoid total body irradiation in the preparatory regimen as far as possible because of its hazardous after-effects which include growth retardation and increased likelihood of secondary malignancies. 18, 19 Our attempt towards achieving more effective eradication of the patient's stem cells and reducing disease recurrence without increasing regimen-related toxicity (RRT) consisted of T cell-depleted allogeneic BMT preceded by the classical preparative protocol of busulfan (BU)-cyclophosphamide (CY) which we intensified by the addition of thiotepa (TTP). Thiotepa is a bialkylating polyfunctional, highly lipid soluble agent, metabolized to tepa via the hepatic P450 system, which has been shown in murine studies and clinical trials to manifest both myeloablative and immunosuppressive activity in hematological malignancies, 12,13.20,21,22 as well as to potentiate engraftment. In murine models there is evidence of enhanced engraftment of donor stem cells, using TTP in the pre-transplant preparative regimen. 21, 23 This finding is attributed generally both to the reduction of stem cell competition through additional myeloablation and, recently, to the immunosuppressive properties of TTP. 23 Our study analyzes engraftment, transplant-related complications and toxicity, including GVHD, survival, diseasefree survival (DFS) and disease recurrence, in 26 consecutive patients suffering from genetic diseases who received a combination of BU-TTP-CY as a conditioning regimen for T cell-depleted allogeneic BMT.
Materials and methods

Patient characteristics
Twenty-six consecutive patients with genetic diseases underwent T cell-depleted BMT from an HLA-identical sibling donor following a preparative regimen of BU-TTP-CY, in our Center. Sixteen patients were male and 10 female. Their median age was 5 (0.2-14) years. Fourteen had ␤-thalassemia major, four osteopetrosis, and the rest had SCID, Wiskott-Aldrich syndrome, familial agranulocytosis, congenital idiopathic hemolytic anemia (CIHA), Gaucher's disease, Niemann-Pick disease, Hurler's syndrome, and adrenoleukodystrophy (one each) ( Table 1) .
Pre-transplant protocol and BMT
All treatment protocols were approved by the Hadassah University Hospital's institutional review board and the Human Experimentation Committee of the Israel Ministry of Health.
The preparative regimen was administered as follows: BU per os (p.o.) 4 mg/kg/day for 4 days (Ϫ8 to Ϫ5), TTP intravenously (i.v.) 5 mg/kg/day for 2 days (Ϫ4 and Ϫ3) and CY i.v 60 mg/kg/day for 2 days (Ϫ2 and Ϫ1). All patients received antibacterial prophylaxis consisting of acyclovir and septrin. Twenty-four hours after completion of the chemotherapy regimen, patients received the allogeneic graft (BM -25 patients, G-CSF-mobilized peripheral blood stem cells (PBSC) -one patient) through a central venous catheter. The median number of cells infused was 1.7 (1.3-3.1) ϫ 10 8 T cell-depleted cells/kg. There was no significant difference in the number of cells infused between patients who received BM and the single patient who received PBSC (data not shown). 14 All patients received cyclosporin (3 mg/kg/day) i.v. from day Ϫ1 to day +100.
Engraftment
Engraftment was defined as an absolute neutrophil count (ANC) of Ͼ0.5 ϫ 10 9 /l and white blood cells (WBC) Ͼ1.0 ϫ 10 9 /l for 3 consecutive days post transplant as well as an untransfused platelet count of Ͼ25 ϫ 10 9 /l for at least 3 consecutive days. 14 
Chimerism
Chimerism was determined by restriction fragment length DNA polymorphism (RFLP) for sex matched donor/recipient pairs, and by amelogenin polymerase chain reaction (PCR) for sex mismatched donor/recipient pairs.
24-26
Toxicity grading
All non-hematologic organ dysfunction from day 0 to day +28 was considered RRT and was graded according to the criteria of Bearman et al. 27 
Statistical analysis
The Kaplan-Meier method was used to calculate probability of survival and DFS. 28 
Results
Engraftment
All patients had myeloid engraftment, but one patient (3.8%), with ␤-thalassemia major, rejected his graft. Twenty-five patients attained ANC Ͼ0.5 ϫ 10 9 /l after a median of 22 (10-56) days, WBC Ͼ1.0 ϫ 10 9 /l after a median of 19 (10-33) days, and platelets Ͼ25 ϫ 10 9 /l after a median of 32 (18-131) days. One patient, with familial agranulocytosis, had protracted thrombocytopenia and died of pulmonary hemorrhage.
Chimerism
Molecular analysis showed that all evaluable patients with genetic diseases who survived at least 1 month post BMT had achieved full donor chimerism, except one patient with Niemann-Pick disease who demonstrated mixed chimerism and 3 months later had overt recurrence of his basic disease.
GVHD
Three patients (11.5%) (␤-thalassemia major -one; Wiskott-Aldrich -one; SCID -one) developed mild grade I-863 Table 2 Transplant-related parameters a Graded according to consensus criteria. WBC = white blood cells; ANC = absolute neutrophil count; Plts = platelets; GVHD = graft-versus-host disease.
II acute GVHD involving the skin and gastrointestinal mucosa, which responded to a brief course of solumedrol. An additional patient with ␤-thalassemia major developed grade IV acute GVHD involving the skin, liver and gastrointestinal tract (Table 2) , and died. One patient with osteopetrosis developed de novo chronic GVHD involving the skin only, which resolved completely after solumedrol therapy ( Table 2) .
Regimen-related toxicity
RRT occurred in 58% of the patients (Table 3 ). The most frequent manifestations were mucositis (58%) and gastrointestinal symptoms (diarrhea, nausea and vomiting) (46%), which in 23% of the patients developed from grade I to grade II (Table 3) . Grade III-IV hepatotoxicity was observed in two patients (7.7%). Both developed severe VOD and required life support (Tables 3 and 4) . Alveolar hemorrhage was the most common form of pulmonary RRT. Four patients (15.5%) (osteopetrosis -one; ␤-thalassemia major -two; familial agranulocytosis -one) experienced pulmonary bleeding, which resulted in death in the patient with marked thrombocytopenia (Tables 3 and 4) . Other organs affected by RRT were the renal, urinary and central nervous systems, but in none of the patients involved did toxicity develop beyond grade III. 
Overall survival, DFS, disease recurrence
Overall survival at 60 months was 77% with 95% confidence intervals (CI) (60-92%) (Figure 1a ). DFS at 60 months was also 77% with 95% CI (62-92%) (Figure 1b) . Only one patient (3.8%) (Niemann-Pick) had disease progression, and subsequently died (Table 4) . Four other patients (15.5%) died of transplant-related causes: grade IV GVHD, VOD, pulmonary hemorrhage and sepsis (Table 4) . The performance status of the surviving patients is excellent (Karnofsky score of 100%).
Discussion
Several studies have demonstrated that long-term survival in genetic diseases is achievable in 70-80% of patients receiving grafts from HLA-identical donors after condition- Table 4 Causes of death ing with BU-CY. [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [29] [30] [31] The Pesaro group recently reported somewhat better results for class I ␤-thalassemia, with 95% survival and 95% event-free survival. 32, 33 However, GVHD, graft rejection, and RRT remain significant risks for these patients. The aim of this study was to evaluate the effectiveness of the addition of 10 mg/kg TTP to the standard BU-CY conditioning regimen for T celldepleted BMT in genetic diseases. TTP has proved to be highly myelosuppressive in a murine model 21 and, recently, to possess immunosuppressive properties too. 23 Overall rates of toxicity were lower than those previously reported in patients with hematological malignancies who received TTP as part of their conditioning; [34] [35] [36] [37] this may be due to the less aggressive chemotherapy given to children with genetic diseases prior to BMT. In this study, mucositis and gastrointestinal tract (GIT) toxicity were the predominant complications, which conforms to the reports from the MD Anderson group [34] [35] [36] [37] and our previous observations. 20 The incidence of VOD was 7.7%, which is substantially lower than the incidence of VOD (48%) recently reported by us in a group of patients with acute leukemia who received TTP as part of their conditioning. 20 Similarly, the incidence of pulmonary toxicity was lower in the patients with genetic diseases (15.5%) than in our previously reported group of patients with acute leukemia who underwent ABMT (45%). The relatively low incidence of both VOD and pulmonary toxicity in the present series of patients may indicate that, contrary to what has previously been suggested, 38 TTP does not play a major role in these complications. In contrast to Dimopoulos et al, 34 we did not observe acute skin toxicity or cardiotoxicity.
There was a relatively low incidence of graft rejection (3.8%) and Ͼgrade III acute GVHD (3.8%). In 25 of the 26 transplanted patients (96%), including 13 of the 14 ␤-thalassemia patients, we observed sustained and stable engraftment, which is comparable to the recent data presented by the Pesaro group on class I and II ␤-thalassemia patients. 32, 33 The overall survival and DFS survival rates were both 71% at 60 months, which is comparable to previously published figures for BMT in genetic diseases, after the conventional BU-CY conditioning regimen. [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] Transplant-related mortality in the present series of patients was comparable to other studies with TTP 20, [32] [33] [34] [35] or without TTP [29] [30] [31] as part of the pre-BMT conditioning. However, since the intensified conditioning regimen we used in order to ensure engraftment of the T cell-depleted graft may result in long-term consequences including growth retardation and infertility particularly in children, other novel approaches, such as non-myeloablative conditioning based on transient immunosuppression induced by fludarabine and anti-T-lymphocyte globulin, should be considered. 39 In conclusion, our data indicate that BU-TTP-CY is an effective preparative regimen for T cell-depleted alloBMT in genetic diseases, providing sustained engraftment, and a very low incidence of GVHD and graft rejection, while transplant-related complications are comparable to other conventional conditioning protocols (eg BU-CY) for this category of diseases. This regimen should be further evaluated and compared to the standard conditioning regimens in prospective randomized trials on large numbers of patients with genetic diseases.
